Literature DB >> 28100431

4CMenB vaccine effectiveness: reasons for optimism.

Nicole E Basta1, Hannah Christensen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28100431      PMCID： PMC5424821          DOI： 10.1016/S0140-6736(16)32061-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Global epidemiology of meningococcal disease.

Authors:  Lee H Harrison; Caroline L Trotter; Mary E Ramsay
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

2.  Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Authors:  María Elena Santolaya; Miguel L O'Ryan; María Teresa Valenzuela; Valeria Prado; Rodrigo Vergara; Alma Muñoz; Daniela Toneatto; Gabriela Graña; Huajun Wang; Ralf Clemens; Peter M Dull
Journal:  Lancet       Date:  2012-01-18       Impact factor: 79.321

Review 3.  The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.

Authors:  Shamez N Ladhani; Helen Campbell; Sydel R Parikh; Vanessa Saliba; Ray Borrow; Mary Ramsay
Journal:  J Infect       Date:  2015-10-02       Impact factor: 6.072

Review 4.  The epidemiology of meningococcal disease and the impact of vaccines.

Authors:  Ameneh Khatami; Andrew J Pollard
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.217

Review 5.  Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Expert Rev Vaccines       Date:  2014-01-06       Impact factor: 5.217

6.  Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.

Authors:  Sydel R Parikh; Nick J Andrews; Kazim Beebeejaun; Helen Campbell; Sonia Ribeiro; Charlotte Ward; Joanne M White; Ray Borrow; Mary E Ramsay; Shamez N Ladhani
Journal:  Lancet       Date:  2016-10-27       Impact factor: 79.321

7.  Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.

Authors:  Nathan James Brendish; Robert Charles Read
Journal:  Expert Rev Vaccines       Date:  2015-02-23       Impact factor: 5.217

8.  Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

Authors:  D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood
Journal:  Lancet       Date:  2013-09-12       Impact factor: 79.321

Review 9.  Enter B and W: two new meningococcal vaccine programmes launched.

Authors:  Shamez N Ladhani; Mary Ramsay; Ray Borrow; Andrew Riordan; John M Watson; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2016-01       Impact factor: 3.791

10.  Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.

Authors:  Hannah Christensen; Caroline L Trotter; Matthew Hickman; W John Edmunds
Journal:  BMJ       Date:  2014-10-09
View more
  9 in total

Review 1.  Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.

Authors:  Rodolfo Villena; Marco Aurelio P Safadi; María Teresa Valenzuela; Juan P Torres; Adam Finn; Miguel O'Ryan
Journal:  Hum Vaccin Immunother       Date:  2018-04-30       Impact factor: 3.452

2.  Promising new vaccine candidates against Campylobacter in broilers.

Authors:  Marine Meunier; Muriel Guyard-Nicodème; Estelle Vigouroux; Typhaine Poezevara; Véronique Beven; S Quesne; Lionel Bigault; Michel Amelot; Daniel Dory; Marianne Chemaly
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

3.  Meningococcal arthritis and myopericarditis: a case report.

Authors:  Lloyd Steele; Katie Bechman; Eoghan De Barra; Charles Mackworth-Young
Journal:  BMC Infect Dis       Date:  2017-12-06       Impact factor: 3.090

4.  NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies.

Authors:  Alessia Liguori; Lucia Dello Iacono; Giulietta Maruggi; Barbara Benucci; Marcello Merola; Paola Lo Surdo; Jacinto López-Sagaseta; Mariagrazia Pizza; Enrico Malito; Matthew J Bottomley
Journal:  mBio       Date:  2018-10-16       Impact factor: 7.867

Review 5.  Proteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines.

Authors:  Benjamin I Baarda; Fabian G Martinez; Aleksandra E Sikora
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

6.  Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy.

Authors:  Pietro Ferrara; Lucia Stromillo; Luciana Albano
Journal:  Medicina (Kaunas)       Date:  2018-12-03       Impact factor: 2.430

7.  Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates.

Authors:  Ronni A G da Silva; Andrey V Karlyshev; Neil J Oldfield; Karl G Wooldridge; Christopher D Bayliss; Ali Ryan; Ruth Griffin
Journal:  Front Microbiol       Date:  2019-12-19       Impact factor: 5.640

Review 8.  The surface lipoproteins of gram-negative bacteria: Protectors and foragers in harsh environments.

Authors:  Gregory B Cole; Thomas J Bateman; Trevor F Moraes
Journal:  J Biol Chem       Date:  2020-12-10       Impact factor: 5.157

9.  Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp.

Authors:  Jacinto López-Sagaseta; Peter T Beernink; Federica Bianchi; Laura Santini; Elisabetta Frigimelica; Alexander H Lucas; Mariagrazia Pizza; Matthew J Bottomley
Journal:  Nat Commun       Date:  2018-02-06       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.